唯科科技(301196) - 2024年7月11日投资者关系活动记录表

Company Overview - Weike Technology specializes in precision injection mold research, design, manufacturing, and sales, expanding into injection parts and health products, becoming a "mold-plastic integrated" large-scale production enterprise [1] - The company has established overseas production bases in Germany, Malaysia, Mexico, the USA, Singapore, and Vietnam since 2018, enhancing its global operational layout [1] Key Achievements - Weike holds over 400 patents, including 23 authorized invention patents, and has been recognized as a key backbone enterprise in China's precision injection mold industry [2] - The company has achieved a high dividend rate of 67% for the year 2023, with plans to increase dividend frequency and rates based on operational performance [2] Client and Market Strategy - Major clients include health appliance companies like Chenbei Group and automotive clients such as Junsheng Electronics and Altcam Group, with a focus on providing integrated solutions [2] - The company’s overseas business accounts for approximately 40% of total revenue, with regional contributions of 39% from Asia, 34% from Europe, and 25% from North America [3] Financial Performance - Revenue from 2020 to 2023 was as follows: 911 million, 1.159 billion, 958 million, and 1.341 billion, with a notable increase of 3.83 billion in 2023 driven by automotive and health appliance sectors [4] - In Q1 2024, the company reported a 37% year-on-year revenue growth and a 16% increase in net profit, with a target of 20% net profit growth for the year [4] Competitive Advantages - Core competencies include high precision injection molds with tolerances of 0.002mm and a lifespan of 1 million cycles, positioning the company close to international standards [2] - The company has established a strong manufacturing platform integrating design, molds, injection, and assembly, with production bases strategically located to meet global client needs [2] Future Outlook - The company is actively seeking quality investment and acquisition targets to enhance performance and shareholder returns, with no expected asset impairment in 2024 [4] - The product strategy aims to maintain high gross margins despite market competition, with a focus on high-margin small-batch products [3]